Dozens of Healthcare Companies Present at Morgan Stanley 24th Annual Global Healthcare Conference in New York

The Morgan Stanley 24th Annual Global Healthcare Conference, held in New York City on September 15-16, 2026, drew a broad cross-section of biotech, pharmaceutical, medtech, and digital health companies presenting their strategies and pipelines to investors. The two-day event featured fireside chats and presentations from companies ranging from large-cap names such as AbbVie to smaller clinical-stage biotechs.

Among the notable themes to emerge from September 16 presentations: Jazz Pharmaceuticals highlighted oncology as a primary growth driver, Amwell detailed a strategic pivot toward government and payer clients, and Evotec used its session to sharpen its investor messaging around its business model. Gyre Therapeutics told investors that operating cash flow is funding its pipeline development, while AVITA Medical signaled a return to revenue growth with costs kept in check.

On the biotech side, clinical-stage companies including Relay Therapeutics, Arvinas, Absci, MBX Biosciences, BioAge Labs, COMPASS Pathways, Structure Therapeutics, and Attovia Therapeutics each presented pipeline updates. Gubra, the Danish obesity-focused biotech, emphasized a deepening pipeline and a longer-term hold strategy for investors. DocGo and Ardelyx also participated on the healthcare services and specialty pharma sides, respectively.

Separately, VERAXA Biotech outlined a precision oncology approach under its ticker VRXA, and Aveanna Healthcare appeared at the concurrent Deutsche Bank 2026 Healthcare Summit, where management described a growth pivot for the home health and hospice provider.